Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.

Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements related to the further development and potential safety, efficacy, commercialization and other characteristics of tanespimycin and Kosan's development plans with respect to tanespimycin, including but not limited to Kosan's plans for the TIME registration program. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of tanespimycin, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Revlimid(R) (lenalidomide) is a registered trademark of Celgene Corporation

Cremophor(R) is a registered trademark of BASF Corporation


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... PharmaTech (Cayman) Inc. (NYSE: WX ) ... general meeting of shareholders held in Hong Kong ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) ... re-election of incumbent Class C directors Dr. Ge ...
... -Asia/ -- Winner Medical Group Inc. (Nasdaq: ... dressings, medical disposables and non-woven PurCotton® materials for the ... preliminary, unaudited financial results for its fiscal fourth quarter ... fourth quarter and year ended results are unaudited and ...
Cached Medicine Technology:WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting 2Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results 2Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results 3Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results 4Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results 5
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... people with sex addiction, pornography affects the brain in ... addicts as they consume drugs, a new study finds. ... patients who have compulsive sexual behavior and healthy volunteers. ... Dr. Valerie Voon, of the University of Cambridge in ... research involved 19 men with sex addiction and a ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- U.S. health officials ... were exposed to live anthrax during a safety mishap ... Control and Prevention officials have announced a moratorium on ... high-level government labs. In a report issued Friday, ... to make sure a similar incident doesn,t occur again. ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional Foods, ... Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, Bifidobacteria, ... ” defines and segments the global probiotics market ... value of probiotic products and ingredients. The report ... the global market with an analysis of trends, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... of data across the Network will help physicians ... Wash., March 17 Virtua Health, a four-hospital ... process improvement, has selected Microsoft Amalga, the unified ... give physicians critical information and insight that help ...
... According to Deloitte SurveyWASHINGTON, March 17 As health care ... of consumers have expressed discontent with the status quo, rating ... A quarter of consumers have skipped care when they were ... done so because they simply could not afford it, were ...
... 17 FRIED LICE: "You don,t have to be such a ... manufacturing company, is set to introduce the latest in delousing technology. ... Disease Control "CDC" website. The guidelines are clear in stating: "to ... of 130 degrees." Lice Safe was able to adapt a ...
... China, March 17 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a leading,developer and distributor of ... medicines (TCM), nutritional and dietary supplements, and,medical ... it will conduct,a conference call at 9:00 ...
... as they perform together , , TUESDAY, March 17 (HealthDay ... harmonize along with the music, according to new European ... of eight pairs of guitarists as they played a ... The study found that brain-wave similarities within and between ...
... costs and prevent preterm births, , , TUESDAY, March 17 (HealthDay ... company,s health insurance for a premature baby could cover the ... new report from the March of Dimes claims. , ... average $4,551, of which about $3,800 is covered by employer ...
Cached Medicine News:Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 2Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 3Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 4Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 5Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 2Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 3Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 4Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 5Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 6Health News:Lice Safe Introduces Licen Tool 2Health News:China Medicine Announces Conference Call to Discuss Fourth and Fiscal Year 2008 Results 2Health News:Musicians' Brain Waves Are Also in Tune 2Health News:Tiniest Babies Carry Biggest Costs 2Health News:Tiniest Babies Carry Biggest Costs 3
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Multi-Tier Shaker...
... incubate and shake up to 16 of AutoGen's ... time. This new system is most appropriate ... Proteinase K digestion. Now you can further ... samples with our AutoIncubator 96 and then placing ...
Medicine Products: